Polyphor AG

POLYPHOR AG

04/06/2020 17:35

EQS-Adhoc: Polyphor shareholders approve all proposals at the Annual General Meeting 2020

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

14/05/2020 07:00

EQS-News: Polyphor announces acceptance of balixafortide abstract at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

05/05/2020 07:00

EQS-Adhoc: Polyphor publishes invitation to the Annual General Meeting 2020

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

28/04/2020 07:00

EQS-Adhoc: Polyphor announces financial results for the full-year 2019

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

30/03/2020 07:00

EQS-Adhoc: Polyphor announces positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III FORTRESS study without modifications

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

20/02/2020 07:00

EQS-Adhoc: Polyphor announces progress of the Phase III immuno-oncology program with balixafortide. Renewed strategy in advancing antibiotics and oncology research and pipeline

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

23/01/2020 18:00

EQS-Adhoc: Polyphor appoints Gökhan Batur as Chief Executive Officer

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

20/11/2019 07:00

EQS-Adhoc: Polyphor announces changes to its Board of Directors

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

23/10/2019 19:00

EQS-News: Polyphor and the University of Zurich announces publication in 'Nature' of the unique mechanism of action of a new class of antibiotics.

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

04/09/2019 17:38

EQS-News: Polyphor to present at the H.C. Wainwright Global Investment Conference

Voir tous les communiqués de Polyphor AG

«
1
2
3
4
5
6
7
8
9
10
»